Atomic AI is an emerging biotechnology company exploiting the cutting-edge fusion of artificial intelligence and structural biology to unlock RNA drug discovery. Based on research prominently featured in Science, Atomic AI's proprietary R&D platform leverages state-of-the-art deep learning foundation models integrated into a virtuous cycle with purpose-designed, in-house wet-lab assays, to discover and design proprietary 3D RNA structural datasets.
Market
RNA drug discovery
Coinvestors
8VC, AME Cloud Ventures, Doug Mohr, FactoryHQ, Greylock, Nat Friedman, Neal Khosla, Not Boring Capital, Patrick Hsu, Playground Global